



ASX Announcement

28 June 2017

Market update on product launches

Creso Pharma Limited (ASX:CPH, the “Company”) is pleased to release an updated investor presentation which provides further information on the Company’s upcoming product launches.

Creso Pharma remains on track to launch its CannaQix® human health nutraceutical product in the area of anxiety and stress in Q1/ Q2 2018 and line extensions in the area of bone metabolism in Q2 2019.

The launch of anibiodiol@2.5 and anibiodiol@80, the proprietary formulated hemp-based complementary feed products for companion and zoo animals also remains on target for 2017.

Creso Pharma will be presenting to investors in Sydney today.

-ENDS-

Investor Enquiries:

Gabriella Hold
M: 0411 364 382
E: gabriella.hold@mcpartners.com.au

Media Enquiries:

Harrison Polites
M: 0409 623 618
E: harrison.polites@mcpartners.com.au

Corporate Queries:

EverBlu Capital
Level 39, Aurora Place
88 Phillip Street, Sydney, NSW 2000
E: info@everblucapital.com
P: +61 2 8249 4000

About Creso Pharma

Creso Pharma brings pharmaceutical expertise and methodological rigour to the world of medical cannabis and strives for the highest quality in its products. It is the leader in cannabidiol (CBD) innovation and develops cannabis- and hemp-derived therapeutic-grade CBD nutraceuticals and medical cannabis products with wide patient reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.



Pioneers bringing
pharmaceutical
industry expertise to
the world of
medicinal cannabis

Dr. Miri Halperin Wernli, CEO

Mr. David Russell, COO

Creso Pharma Ltd Disclaimer



This presentation has been prepared by Creso Pharma Limited [Company or Creso]. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial product advice or advice relating to legal, taxation or investment matters.

This presentation and the information contained herein and all electronic and/or hard copy documentation which comprise it are being provided to you solely for your information and may not be copied, reproduced, distributed, disclosed or published, in whole or in part, to any other person for any purpose whatsoever at any time without the prior written consent of Creso. This presentation is not an offer to any person nor is it a prospectus.

Creso has prepared this document based on information available to it at the time of preparation. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, options or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecast or projections set out in this presentation.

This presentation is not investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. The information contained in this presentation has been prepared without taking into account the objectives, financial situation or needs of individuals.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future Matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospectus may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipient's should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 [Securities Act]. The Company's shares have not been, and will be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including any exemption for qualified institutional buyers.



**CEO Headquartered in Zug, Switzerland
COO based in Sydney, Australia**

Global development and commercialization of pharmaceutical grade cannabis and hemp derived therapeutic products using innovative delivery technologies

- 1) GMP sourcing only
- 2) Standardised full-plant extraction
- 3) Owning unique delivery methods
- 4) Quality sales & distribution channels
- 5) Clinical Trials in human and animal health
- 6) IP development across the value chain

IPO Oct 2016	\$m	Oversubscribed
Capital Raising Mar 2017	\$m	Oversubscribed
Market Cap @ 51.5 cents*	\$m	45.5m
Cash at Hand	\$m	~10m
Enterprise value	\$m	~35.5m
Shares on Issue	no.	88.3m
Top 20 shareholders	%	51.1%
Escrowed Shares	No.	15.6m [29.9% of Shares On Issue]

*As At June 26




- The medicinal cannabis industry is in its infancy and dominated by small players with minimal understanding of what is required to comply with emerging regulations
- This has led to questionable quality due to the lack of standardization in formulation and dosage of cannabis derived products
- There is a remarkable lack of trusted cannabis brands in the global marketplace
- Established pharmaceutical companies are generally reluctant to enter the market due to evolving regulations

*Creso brings
significant
pharmaceutical
industry expertise
and rigor to the
world of medicinal
cannabis*

Creso Pharma brings pharmaceutical expertise and methodological rigor to the world of medical cannabis and strives for the highest quality in its products.

Creso Pharma is the leader in cannabidiol (CBD) innovation and develops cannabis and full plant hemp-derived therapeutic grade CBD nutraceuticals and medical cannabis products with wide patient reach for human and animal health.

Creso Pharma Ltd
Two Distinct Divisions



Creso Pharma Ltd
Board of Directors



**Dr. Miri
Halperin Wernli**
**CEO &
Co-Founder**

Dr. Halperin Wernli is a senior pharma executive with over 25 years of strategic and operational leadership in global drug and product development in the pharmaceutical and biomedical industries. She held worldwide executive leadership positions in R&D and in strategic marketing within global pharmaceutical companies in Switzerland and in the US.



**Boaz
Wachtel**
**Chairman & Co-
Founder**

Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical [MMJ.ASX], Australia's first publically traded medical cannabis company. He initiated and helped implement the National Medical Cannabis Program in Israel. Mr. Wachtel is a certified Clinical research manager and holds an MA in management and marketing from the University of Maryland



Adam Blumenthal
**Non-Executive
Director &
Co-Founder**

Mr. Blumenthal has 10 years experience in investment banking and corporate finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of listed and unlisted companies. He has successfully brought to market several medical cannabis companies spanning Israel, Canada, Switzerland and Australia.



**Dr. James
Ellingford**
Non-Executive Director

Dr. Ellingford's professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA. He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.



David Russell
Chief Operating Officer

Mr. Russell has more than 25 years' experience within the pharmaceutical and biotech industry with a number of leading global companies including Roche, Actelion, Celgene and Novogen. In particular, he has been responsible for building, leading and growing commercial teams and product launches in China, Australia and Asia in a number of therapeutic areas.



Jorge Wernli
Industry Advisor

Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies and start-ups. Previously he dealt with and built relationships with Ministries of Health in Europe, South America and selected Asian countries.



Dr. Gian Trepp
Industry Advisor

Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership. He held worldwide executive leadership positions in General Management and Marketing within global pharmaceutical companies in Switzerland and in the US. He is the founder and owner of GBT Pharma, UK.

Creso Pharma Ltd
Scientific Advisory Board



**Dr. Isaac
Kobrin**
Industry Advisor

Dr. Isaac Kobrin is an internist with 15 years experience in the academic medicine both in Israel and the USA. He has over 22 years of experience in the Pharma Industry in Roche and Actelion. He has been responsible for the worldwide development of key compounds and has held numerous leadership positions in medical organisations.




**Dr. Stéphane
Redey**
Industry Advisor

Dr. Stéphane Redey has over 18 years experience leading teams in the technical development of innovative drugs and strategic outsourcing. He has held senior positions with global responsibilities in pharmaceutical companies in both Switzerland and Australia. He has led successful international collaborations with companies on four continents.




**Dr. Raquel
Peyraube**
Industry Advisor

Dr. Raquel Peyraube is a specialist in the drug field with more than 28 years experience. Throughout her career she has been involved in training, prevention, treatment and harm reduction, developing innovative approaches emphasising ethical issues which has earned her international recognition. Dr Peyraube is currently a consultant on drug policy reform in Latin America.



**Prof. Dr. med Felix
Gutzwiller**
Industry Advisor

Felix Gutzwiller holds the titles of MD of the University of Basel, an MPH of the Harvard School of Public Health, Dr. PH of the Johns Hopkins University School of Hygiene and Public Health. He was a Professor at the University of Basel and a Professor of Social and Preventive Medicine at the University of Zürich (1988-2013), Emeritus since 2013.





Fills void in current market with growing need for **trusted products** that meet the highest global pharmaceutical standards



Near-term revenues
Product launches in the EU of animal [2017] and human [2018] products



Growing market opportunity with **six plus products in pipeline** targeting human and animal nutraceutical markets



Exclusive licensing deals that gives Creso access to unique drug delivery IP



Diversified revenue stream targeting human and pet health markets




Large **global market** that is only at the start of its growth trajectory




Company well placed to be the **“gold standard”** in cannabis and hemp derived therapeutics

Why Cannabis?



Creso only uses full plant extracts. Cannabinoids and other compounds have a greater effect when taken together than when separated into individual single compounds - potentially resulting in a synergetic “Entourage Effect”¹


Think: Soloist vs. Symphony or Grape vs. Wine




Market Potential

- **Australia:** No credible data exists for Australian potential but figures of ~150m are reasonable
- **Global:** Sales now exceeding \$7 billion and growing fast
- **US:** A 3 million-patient market opportunity (More than 700K patients have already been prescribed) and adult use/recreational cannabis is coming on-line in several states
- **Canada:** Estimated at \$144 million in 2014, rising to \$380 million by 2018, to \$1.3 billion in the next 10 years as adult use is established
- **Europe:** Vast unmet demand. Small quantities usually imported from Holland's only national medical-grade cannabis (MGC) program supplier - Bedrocan.

ArcView & BDS Analytics



New Frontier Analytics





Nutraceuticals are a multi-billion dollar industry

- Reached **\$217 billion** in 2017#
- The nutraceutical ingredient market is forecast to reach **\$33.6 billion** by 2018
- The overall US nutrition market was estimated at **\$137.4 billion** in 2012, with supplements accounting for **\$32.4 billion**



Multiple drivers for continued growth

- Rising health concerns, the growth of key demographics and growing consumer desire to lead a healthy life and avoid dependence on synthetic drugs are identified trends that show no sign of slowing down



Extremely lucrative for food and beverage companies

- Comparatively high margins
- Minimal regulatory requirements
- Germany, Switzerland, Netherlands, and Sweden have emerged as the key nutraceutical innovation hubs in Europe

#Euromonitor, VDS Trends 2017. US\$

The market for nutraceutical cannabinoids is still untapped

1

Generally, no GMP-certified production to produce standardized high-grade plant extracts

2

Lack of efficacious delivery systems to ensure sufficiently high bioavailability

3

Lack of seasoned pharmaceutical executives to develop products and launch brands in this area

The Creso Advantage



CRESO
COSMETICS



CRESO
THERAPEUTICS



CRESO
TERPENES



CRESO
SWISS
NUTRACEUTICALS




CRESO
ANIMAL HEALTH


Euromonitor, 2017 Global Forces: Vitamin and Dietary Supplements [VDS] Major Consumer Trends Driving Demand



- Consumers looking towards prevention
- More mobile and informed consumers
- Rising health costs and insurance
- More regulated claims and quality
- E-commerce sales are growing
- VDS Technology becoming personalised



Euromonitor, 2017 Global Forces: Vitamin and Dietary Supplements [VDS] Creso Plans LATAM and APAC for SwissVit®



Note: % retail value CAGR 2011-2016 (USD million, fixed exchange rate).



Full Plant CBD-rich
Nutraceuticals

Animal Hemp-based Complementary Feed

- anibidiol® 2.5 Small Companion Animals
- anibidiol® 80 Large Companion and Zoo Animals
- anibidiol® 100 Small Companion Animals
- anibidiol® 400 Large Companion and Zoo Animals

Human Health

- CannaQix® in 1st Proprietary delivery system
- CannaQix® in 2nd Proprietary delivery system
- CannaQix® Line extension in proprietary delivery systems


Anxiety/Stress

Bone

Medical Cannabis
& SwissVit

Human Health

- SwissVit™ Range of nutraceuticals in INNutriGEL SoftGum® technology
- Australia Medicinal Cannabis [CanniMed®]
- Australia Medicinal Cannabis [Cannapharm AG]



● Launch

Creso has 4 Hemp-based Complementary Feed Products for Small Companion Animals and Large Companion and Zoo Animals

Launch planned for Q4 2017 and Q1 2018

1

anibidiol® 2.5 and anibidiol® 80 are aimed at small companion animals (e.g. dogs) and at large companion animals and zoo animals - mainly targeting stress and behavioural problems, chronic pain (mainly arthritis), and aches of senior aging animals



2

anibidiol® 100 and anibidiol® 400 are aimed at small companion animals (e.g. dogs) and at large companion animals and zoo animals mainly targeting stress and behavioural problems, chronic pain (mainly arthritis), and aging aches of senior aging animals

- Globally 33% of households have a dog and consider them part of the family¹
- The recession-resistant animal health products industry is projected to continue showing rapid growth
- One of the biggest challenges of pet ownership is maintaining pets health
- 41% of pet owners have considered or tried various alternative therapies including:
 - Nutritional supplements [29%]
 - Herbal remedies [7%]
 - Homeopathy [4%]



- Hemp-based nutraceutical targeting stress and mental focus
- Stimulates psychological performance to reduce stress, and enhance mental focus and overall health
- In proprietary delivery technologies enhancing bioavailability and absorption
- Reliable & safe, non-euphoric, non-addictive
- Strong scientific rationale to back the introduction on the market
- Product Launch Q1 2018 following regulatory clearance and market authorization



Creso Pharma Ltd

SwissVit for LATAM and APAC



Product number: 1018-02-04	Color: Red	Soft Gum™ weight: 4.5g
Flavor: Strawberry	Shape: Cone	INNUTRI

SwissVit Immunity SoftGums™

SwissVit Immunity features SoftGums™ technology which enables the optimal buccal bioavailability and absorption of vitamins and minerals helpful in supporting normal cellular and immune function. SwissVit Immunity Soft Gums™ are a pleasant tasting, easy to ingest multivitamin formulation that enables patients to supplement their daily intake of immune supporting vitamins and minerals.



Swiss by Name, Swiss by Nature.
Vitality Precisely

Ingredients

Glucose syrup, sugar, modified starch, water, vitamin and mineral composition (A, D3, E, B1, B6, folic acid, B12, C, selenium and zinc), acidifier (citric acid), acidity regulator (sodium citrate), natural flavour, coating material (carnauba wax), colouring foodstuffs (concentrate from radish, apple and blackcurrant).



SoftGums™

SoftGums™ is a patented product by the Swiss company INNUTRIGEL manufactured in Germany specifically for Creso Swiss Nutraceutical products. The buccal delivery offers high bioavailability and absorption along with a palatable texture suited for all ages. The easy to ingest SoftGums™ are vegetarian, lactose, gluten free and can be vegan, halal and kosher. The SoftGums™ are also heat resistant to around 70°C and non-sticky compared to other products.

Nutritional Values

	Per 10 Soft Gums™	% RDA* for Europe
Calories	105 kcal (231 kcal)	
Total Fat	0.00 g	0.00 %
Saturated Fat	0.00 g	0.00 %
Sodium Chloride	1.00 g	
Sugars	1.00 g	
Protein	0.00 g	
Salt	0.00 g	
Vitamin and Mineral Composition		
Vitamin A	100 µg	100 %
Vitamin B1	1 mg	100 %
Vitamin B2	20 µg	100 %
Vitamin B6	1.0 mg	100 %
Vitamin B12	1.4 µg	100 %
Folic acid	100 µg	100 %
Vitamin B12	1.4 µg	100 %
Vitamin C	40 mg	100 %
Selenium	10 µg	100 %
Zinc	10 mg	100 %

*% RDA based on reference values

GMO-Status

This product does not fall under the scope of Regulation (EC) No. 1825/2003 on genetically modified food and feed nor under the scope of Regulation (EC) No. 1831/2003 (incl. their subsequent amendments). Therefore, this product stated above does not require labelling as a GMO, as defined in Regulations above mentioned.

	Allergen Information This product does not contain allergens according to Regulation (EC) No. 1181/2011.	
	Shelf life 18 months from date of manufacturing	
	Storage Store in a cool and dry place	

- Creso/INNutriGEL Soft Gums™
- A range of Premium Swiss Nutraceuticals in Patent Protected proprietary technology
- Buccal delivery for precise dosing, immediate release and increased absorption into the circulation
- Avoids respiratory irritation or first-pass effect associated with other delivery technologies
- Easy to ingest, heat resistant, vegan, halal, kosher, gluten and lactose free, palatable

- Creso Pharma's Australian partner, Health House International, successfully imported the first medicinal cannabis products into Australia in May 2017 following changes to Government legislation
- Import was a range of three cannabis oils for human health from Canadian manufacturer CanniMed
- The oils can be used for a variety of conditions as approved by prescribing physicians under Australian Federal and State laws and regulations to meet immediate need for medicinal cannabis locally
- Products will now be distributed to authorised pharmacies by Health House



- LOI Signed with Cannapharm AG, Switzerland to exclusively distribute the fully GMP Swiss medical cannabis products in selected territories
- Two Forms – Tincture and Oil
- THC/CBD
 - 10:20 in the alcohol extraction
 - 10:25 in the hemp oil extraction
- Exclusive Territory: Australia, New Zealand, China, Brazil, Mexico, Chile, Colombia



SwissVit SoftGums® using propriety INNutriGEL patents via distribution agreement in Latin America and under assessment are Australia, China and Asia-Pacific

Local cultivation and product development via the partnership with LeafCann Australia

Clinical Trials under consideration by the Scientific Advisory Board in Anxiety, Stress and Dementia using Swiss GMP CBD/THC products


Terpene based products using formulations unique to Creso and linked to proprietary technologies with global exclusivity

Enter edibles market with proprietary hemp based products

Cosmetics projects "A" and "B" with propriety CBD rich full-plant extracts

Creso is developing a nutraceutical approach for both human and vet markets using hemp based full-plant medical grade CBD-rich nutraceutical products which are efficacious, safe, standardized in composition and dose

1. **GMP sourcing only:** nutraceutical products from GMP-certified plants located in Europe, syndicated to our needs
2. **Standardized extraction:** GMP- and/or ISO-compliant extraction processes, to supply products of excellent quality, purity, and safety
3. **Owning and developing unique delivery methods:** source and license innovative and proven delivery platforms including tablets and sublinguals to increase absorption and bioavailability
4. **Sales and distribution channels:** Products and brands will always be registered with local health authorities so diverse commercial channels can be used
5. **Clinical trials:** perform small-scale clinical trials to gain scientific data
6. **IP:** Secure IP across the value chain



Product Development and Launches are in process and on track

Hemp-based Complementary Feed Products for Companion and Zoo Animals launches in the EU by end of 2017

Human health Nutraceutical product launches in the EU/CH in 2018

Various GMP Medicinal Cannabis products in Australia by end of 2017

Hemp Industries products organic growth off a small base

Investment Summary

Develop Products

Launch Brands



Assess North American cannabis industry for opportunities



Global product and market development - launch readiness

Q2CY2017



Pioneer Medicinal Cannabis in Australia
Pre-launch of hemp-based Complementary Feed Products for Companion and Zoo Animals in Switzerland and selected EU in 1st proprietary delivery technology



Q3CY2017



Launch of first-generation human health nutraceutical product for anxiety and stress in 1st innovative delivery technology



Launch of second-generation human health nutraceutical human health product for anxiety and stress based in 2nd innovative delivery technology



Launch of hemp-based Complementary Feed Products for Companion and Zoo Animals in Switzerland and selected EU in 2nd proprietary delivery technology

CY2018



Rapidly Growing Markets

- Increasing scientific evidence on efficacy of cannabis-based treatments
- Existing markets are expanding and new markets opening
- More countries are liberalising medicinal cannabis

Increased Consumer Demand



Strongly Performing Sector

- Investor interest in sector is strong
- 50+ companies with business based largely on legal marijuana
- Industry in infancy with plenty of room to grow

Strong Sales Revenue



“Gold Standard”

- Creso brings pharmaceutical industry rigour and professionalism to medicinal cannabis market
- Company well placed to be the gold standard in cannabis and hemp derived therapeutics

Industry Leadership



Sound Business Model

- Near-term revenues
- Diversified revenue streams from human and pet health markets
- Best practice for CBD extraction and drug delivery
- Resources in place for global sales

Strong Company Returns



CRESO

PHARMA

Creso Pharma Ltd
Contact Information



Creso Pharma Limited

t: +61 8 6381 0054
e: info@cresopharma.com
w: www.cresopharma.com
a: Level 4, 11 Ventnor Avenue
West Perth WA Australia

Mirador Corporate
Company Secretary

t: +61 8 6381 0054
a: Level 4, 11 Ventnor Avenue
West Perth WA Australia

EverBlu Capital
Corporate Advisor

t: 02 8249 0000
e: info@everblucapital.com
w: www.everblucapital.com
a: Level 39, Aurora Place,
88 Phillip Street,
Sydney NSW Australia